Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in moderate to severe atopic dermatitis
NCT03706040Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of risankizumab in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Dec 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03706040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706040.